secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078596
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially
--------------------------------------------------------------------------------

- EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.
- Total Q2 net sales $6.3M (flat YoY); SimpliDerm $2.0M (down from $2.6M); Cardiovascular $0.7M (down from $1.1M).
- GAAP gross margin improved to 48.8% (vs 44.5%); adjusted gross margin 62.4% (vs 58.0%); net loss narrowed to $9.6M (vs $28.2M).
- Litigation substantially resolved: settled 27 additional FiberCel cases for total 97 of 110; expect reduced litigation expenses.
- Pipeline: progressing NXT-41 antibiotic biomatrix for breast reconstruction; FDA clearance targeted 2H26 (base) and 1H27 (drug-eluting); addresses $1.5B market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925078596/0001104659-25-078596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925078596/tm2523438d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer